• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation

Thumbnail

View/Open

Tam Metin / Full Text (1.983Mb)

Date

2020

Author

Karadag, Cihan
Akar, Bertan
Gonenc, Gokcenur
Aslancan, Reyhan
Yilmaz, Nagihan
Caliskan, Eray

Metadata

Show full item record

Citation

Karadag, C., Akar, B., Gonenc, G., Aslancan, R., Yilmaz, N., & Caliskan, E. (2020). Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 33(11), 1934–1939. https://doi.org/10.1080/14767058.2019.1671348

Abstract

Objective: The aim of this study was to compare the effects of low molecular weight heparin (LMWH), LMWH plus low dose aspirin, or low dose aspirin only on pregnancy outcomes in recurrent pregnancy loss (RPL) patients with factor V Leiden mutation (FVLM). Materials and methods: A total of 2764 RPL patients were evaluated in for the etiology of RPL. Mutations in factor V Leiden homozygous and heterozygous were determined. Subsequently, 196 of these patients were diagnosed with FVLM and included in the study; of these 174 completed the study. At the sixth week of gestation of subsequent pregnancy participants were randomly distributed into three groups. Group A (n?=?61) was composed of patients with an oral dose of 100?mg aspirin daily, Group B (n?=?59) consisted of patients using 40?mg enoxaparin and 100?mg orally aspirin daily, and Group C (n?=?54) included patients using 40?mg enoxaparin daily during pregnancy. Results: Among the 174 patients who completed the study, the live birth and miscarriage rates were similar for the three groups (p?=?.843 and p?=?.694, respectively). There was no significant difference among the groups in rates of eclampsia, placental abruption, intrauterine fetal growth restriction and gestational diabetes mellitus. The number of preeclamptic patients was significantly higher in Group A than Groups B and C. The levels of preterm birth was significantly higher in Group A than Groups B and C. Conclusion: Using low dose aspirin, LMWH plus aspirin, or LMWH alone yielded comparable live birth rates in RPL patients with FVLM. However, LMWH decreased the risk of preeclampsia in this group of patients. LMWH might therefore have a preventive role regarding preeclampsia.

Source

Journal of Maternal-Fetal & Neonatal Medicine

Volume

33

Issue

11

URI

https://doi.org/10.1080/14767058.2019.1671348
https://hdl.handle.net/20.500.12713/551

Collections

  • Makale Koleksiyonu [26]
  • PubMed İndeksli Yayınlar Koleksiyonu [890]
  • Scopus İndeksli Yayınlar Koleksiyonu [1274]
  • WoS İndeksli Yayınlar Koleksiyonu [1330]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@İSÜ

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || İstinye University || OAI-PMH ||

İstinye University, İstanbul, Turkey
If you find any errors in content, please contact:

Creative Commons License
İstinye University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@İSÜ:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.